المؤلفون: Enrico Franceschi, Didier Frappaz, Roberta Rudà, Peter Hau, Matthias Preusser, Caroline Houillier, Giuseppe Lombardi, Sofia Asioli, Caroline Dehais, Franck Bielle, Vincenzo Di Nunno, Martin van den Bent, Alba A. Brandes, Ahmed Idbaih, EURACAN Domain, Paul Clement Radek, Lakomý Nicolai El-Hindy, Jean-Yves Delattre, Ville Vuorinen, Silvia Scoccianti, Riccardo SoffiettiLucia Monti, Andrea Pace, Gaetano Finocchiaro, Arimantas TamasauskasMark ter Laan, Anja Gijtenbeek, Michiel Wagemakers, David NoskeUroš Smrdel, Puneet Plaha, Naomi Fersht

المصدر: Frontiers in Oncology, Vol 10 (2020)

مصطلحات موضوعية: pineal tumors, mesenchymal non meningothelial intracranial tumors, CNS lymphoma, germ cell tumors, pituitary tumor, glioneural tumor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/article/10.3389/fonc.2020.00996/fullTest; https://doaj.org/toc/2234-943XTest

الوصول الحر: https://doaj.org/article/3617bb6cee8e40aa8f575d602ec52f33Test

المؤلفون: ESMO Guidelines Comm, EURACAN, GENTURIS, Gronchi, A., Miah, A. B., Dei Tos, A. P., Joensuu, H., Martin-Broto, J.

المساهمون: University of Helsinki, Research Programs Unit, Department of Oncology, Heikki Joensuu / Principal Investigator, HUS Comprehensive Cancer Center

مصطلحات موضوعية: sarcoma, soft tissue sarcomas, retroperitoneal sarcoma, uterine sarcoma, desmoid, Clinical Practice Guideline, PHASE-II TRIAL, SOLITARY FIBROUS TUMOR, ENDOMETRIAL STROMAL SARCOMA, CASE SERIES ANALYSIS, LONG-TERM EFFICACY, RADIATION-THERAPY, ADJUVANT CHEMOTHERAPY, DOUBLE-BLIND, HIGH-GRADE, RETROSPECTIVE ANALYSIS, 3122 Cancers

وصف الملف: application/pdf

العلاقة: Patient representatives Markus Wartenberg and Gerard van Oortmerssen from Sarcoma Patients EuroNet (SPAEN) who attended the consensus meeting as observers and contributed the valuable perspectives of patients to the consensus process. The authors thank Louise Green and Richard Lutz of the ESMO Guidelines staff for their support throughout the whole consensus process and Jackie Jones of JJ Medical Communications Ltd for her logistical support during the virtual consensus meeting. This support was funded by ESMO. Manuscript editing support was provided by Richard Lutz, Catherine Evans and Louise Green (ESMO Guidelines staff). Nathan Cherny, Chair of the ESMO-MCBS Working Group, Urani Dafni ESMO-MCBS Working Group Member/Frontier Science Foundation Hellas and Giota Zygoura of Frontier Science Foundation Hellas provided review and validation of the ESMO-MCBS scores. Nicola Latino (ESMO Scientific Affairs staff) provided coordination and support of the ESMO-MCBS scores and preparation of the ESMO-MCBS table.; ESMO Guidelines Comm , EURACAN , GENTURIS , Gronchi , A , Miah , A B , Dei Tos , A P , Joensuu , H & Martin-Broto , J 2021 , ' Soft tissue and visceral sarcomas : ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up ' , Annals of Oncology , vol. 32 , no. 11 , pp. 1348-1365 . https://doi.org/10.1016/j.annonc.2021.07.006Test; ORCID: /0000-0003-0281-2507/work/104575939; http://hdl.handle.net/10138/575129Test; d2503d81-c0ba-4e46-8b6d-78cc3dbf7b03; 000710498800008

الإتاحة: http://hdl.handle.net/10138/575129Test

المؤلفون: ESMO Guidelines Comm, EURACAN, GENTURIS, Casali, P. G., Blay, J. Y., Abecassis, N., Joensuu, H., Morosi, C.

المساهمون: Heikki Joensuu / Principal Investigator, HUS Comprehensive Cancer Center, Department of Oncology, Clinicum, University of Helsinki

مصطلحات موضوعية: GIST, clinical practice guidelines, gastrointestinal stromal tumour, surgery, tyrosine kinase inhibitor, PHASE-II TRIAL, NEOADJUVANT/ADJUVANT IMATINIB MESYLATE, ADJUVANT IMATINIB, SOFT-TISSUE, EMISSION-TOMOGRAPHY, CARNEY-STRATAKIS, RANDOMIZED-TRIAL, NATURAL-HISTORY, TYROSINE KINASE, DOSE IMATINIB, 3122 Cancers

وصف الملف: application/pdf

العلاقة: We acknowledge patient representatives Gerard van Oortmerssen and Marcus Wartenburg from Sarcoma Patients EuroNet (SPAEN), who attended the consensus meeting as observers and contributed the valuable perspectives of patients to the consensus process. The authors thank Louise Green and Richard Lutz of the ESMO Guidelines staff for their support throughout the whole consensus process and Jackie Jones of JJ Medical Communications Ltd for her project management support during the virtual consensus meeting. This support was funded by ESMO. Manuscript editing support was provided by Louise Green and Catherine Evans (ESMO Guidelines staff). Nathan Cherny, Chair of the ESMO-MCBS Working Group, Urani Dafni ESMO-MCBS Working Group Member/Frontier Science Foundation Hellas and Giota Zygoura of Frontier Science Foundation Hellas provided review and validation of the ESMO-MCBS scores. Nicola Latino (ESMO Scientific Affairs staff) provided coordination and support of the ESMO-MCBS scores and preparation of the ESMO-MCBS table. Dr Joaquin Mateo (Chair of the ESMO Translational Research and Precision Medicine Working Group) provided validation support for integration of ESCAT scores into this guideline. Dr Svetlana Jezdic (ESMO Medical Affairs Advisor) provided coordination and support of the ESCAT scores and their presentation in the table.; ESMO Guidelines Comm , ESMO Guidelines Comm , EURACAN , GENTURIS , Casali , P G , Blay , J Y , Abecassis , N , Joensuu , H & Morosi , C 2022 , ' Gastrointestinal stromal tumours : ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up ' , Annals of Oncology , vol. 33 , no. 1 , pp. 20-33 . https://doi.org/10.1016/j.annonc.2021.09.005Test; ORCID: /0000-0003-0281-2507/work/105907538; a4dfae4f-b7fd-4cb4-b0d7-1d23418a61ac; http://hdl.handle.net/10138/568962Test; 000731865200006

الإتاحة: http://hdl.handle.net/10138/568962Test

المؤلفون: ESMO Guidelines Comm, EURACAN, GENTURIS, ERN PaedCan, Strauss, S. J., Frezza, A. M., Abecassis, N., Hassan, A. B., Joensuu, H., Pousa, A. Lopez

المساهمون: University of Helsinki, Department of Oncology, Heikki Joensuu / Principal Investigator, HUS Comprehensive Cancer Center

مصطلحات موضوعية: bone sarcoma, clinical practice guideline, diagnosis, treatment, follow-up, management, LOCALIZED EWING SARCOMA, GIANT-CELL TUMOR, MALIGNANT FIBROUS HISTIOCYTOMA, HIGH-GRADE OSTEOSARCOMA, HIGH-DOSE IFOSFAMIDE, OPEN-LABEL, PHASE-II, NEOADJUVANT CHEMOTHERAPY, PROGNOSTIC-FACTORS, MURAMYL TRIPEPTIDE, 3122 Cancers

وصف الملف: application/pdf

العلاقة: No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds.; ESMO Guidelines Comm , EURACAN , GENTURIS , ERN PaedCan , Strauss , S J , Frezza , A M , Abecassis , N , Hassan , A B , Joensuu , H & Pousa , A L 2021 , ' Bone sarcomas : ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up ' , Annals of Oncology , vol. 32 , no. 12 , pp. 1520-1536 . https://doi.org/10.1016/j.annonc.2021.08.1995Test; ORCID: /0000-0003-0281-2507/work/105283804; c0ec00b8-527d-4a1e-9c1d-effd098bdcc0; http://hdl.handle.net/10138/568428Test; 000721610600011

الإتاحة: http://hdl.handle.net/10138/568428Test

المؤلفون: Bossi, P, Chan, A T, Licitra, L, Trama, A, Orlandi, E, Hui, E P, Halámková, J, Mattheis, S, Baujat, B, Hardillo, J, Smeele, L, van Herpen, C, Castro, A, Machiels, J-P, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, EURACAN

المساهمون: UCL - (SLuc) Centre du cancer, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale

المصدر: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 32, no.4, p. 452-465 (2021)

مصطلحات موضوعية: Follow-Up Studies, Humans, Medical Oncology, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Neoplasm Staging, Societies, Medical, Clinical Practice Guidelines, diagnosis, follow-up, nasopharyngeal cancer, treatment

العلاقة: boreal:258802; http://hdl.handle.net/2078.1/258802Test; info:pmid/33358989; urn:EISSN:1569-8041

الإتاحة: https://doi.org/10.1016/j.annonc.2020.12.007Test
http://hdl.handle.net/2078.1/258802Test

المؤلفون: ESMO Guidelines Comm EURACAN, Rutkowski, P., Safwat, A. A., Schöffski, P., Sleijfer, S., Stacchiotti, S., Sundby Hall, K., Unk, M., Van Coevorden, F., Van der Graaf, W. T. A., Whelan, J., Wardelmann, E., Zaikova, Olga, Blay, J. Y.

المساهمون: Heikki Joensuu / Principal Investigator, Department of Oncology, Clinicum

مصطلحات موضوعية: RPS WORKING GROUP, ENDOMETRIAL STROMAL SARCOMA, DESMOID-TYPE FIBROMATOSIS, RANDOMIZED PHASE-II, ADJUVANT RADIATION-THERAPY, ISOLATED LIMB PERFUSION, NECROSIS-FACTOR-ALPHA, CASE-SERIES ANALYSIS, RARE CANCER NETWORK, RETROPERITONEAL SARCOMA, 3122 Cancers

وصف الملف: application/pdf

العلاقة: PGC has reported advisory roles for Deciphera Pharmaceuticals, Eisai, Eli Lilly, Nektar Therapeutics, speaker's honoraria from Eisai, Eli Lilly, Pfizer, PharmaMar, and conducted studies sponsored by Amgen Dompe, AROG Bayer, Blueprint Medicines, Eli Lilly, Daiichi Sankyo Pharma, Epizyme, GlaxoSmithKline, Novartis, Pfizer, PharmaMar; SBa has reported research support from Novartis, Incyte, Blueprint Medicines, has received honoraria or consultation fees from Novartis, Lilly, Pfizer, PharmaMar and Bayer; SBi has reported advisory/consultant roles for Lilly, Bayer, Pfizer, Novartis, Isolfol and Clinigen and conducted studies sponsored by Janssen-Cilag, Eisai and Loxo Oncology; SBo has reported honoraria and travel grants from Nanobiotix and Lilly and received travel grants from PharmaMar; IB has received research funds from Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Roche, Amgen and has reported advisory roles for AstraZeneca, Roche, Merck Sharp & Dohme, LEO Pharma, Amgen, Bristol-Myers Squibb, Pfizer and Novartis; TB has reported honoraria from Roche and PharmaMar and advisory board and honoraria from Amgen, Bayer, Novartis, Eisai and Eli Lilly; JMB has reported consulting advisory role for PharmaMar, Lilly, Bayer, Novartis and being a member of the speaker's bureau for PharmaMar and received travel grants from PharmaMar and Lilly; APDT is a member of the speakers' bureau for Lilly, Pfizer and Merck Sharp & Dohme; XGDM has reported advisory role for Lilly, PharmaMar and Novartis; PD has reported conducted research sponsored by Eli Lilly; ME has participated in advisory boards for Bayer, Sobi, Lilly, Eisai and Novartis; AMF has conducted studies sponsored by Amgen Dompe, AROG Bayer, Blueprint Medicines, Eli Lilly, Daiichi Sankyo Pharma, Epizyme, GlaxoSmithKline, Novartis, Pfizer, PharmaMar; SG has received research grants and honoraria from Novartis, Pfizer and Bayer; HG has received research grants from Novartis, Daiichi Sankyo Pharma and Pfizer; AG has reported compensation for advisory boards from Novartis, Pfizer, Bayer, Lilly, PharmaMar and Nanobiotix, honoraria from Novartis, Lilly, PharmaMar and Nanobiotix, and research funds from PharmaMar and travel grants from PhramaMar and Nanobiotix; BH has received research grants from EuroSarc and has conducted research with EIT Health in collaboration with GE healthcare and Philips, he has received reagents from Takeda and Astellas to conduct clinical trials without direct funding; PH has reported conducting research sponsored by Novartis, Blueprint Medicines, Nanobiotix and Lilly and has received honoraria and travel grants from PharmaMar, Eisai and Lilly; HJ has reported co-appointment with Orion Pharma and holds stock in Sartar Therapeutics, Faron Pharmaceuticals and Orion Pharma; RLJ is a consultant for Adaptimmune, Blueprint Medicines, Clinigen, Eisai, Epizyme, Daichii, Deciphera, Immunedesign, Lilly, Merck and PharmaMar; IJ has received honoraria from Lilly for lectures; PJ has reported being a consultant for Stryker for the design of a new tumour prosthesis; BK has reported honoraria from Novartis, Pfizer and Bayer and advisory role for Bayer; KK has received travel grants from Novartis and Pfizer; ALC has received honoraria from Pfizer, Novartis, Lilly, Amgen, Bayer and PharmaMar; Pfizer and Bayer; IL has received honoraria from Bristol-Myers Squibb, MDS, Roche, Novartis and Pfizer for scientific presentations or research; MAP has served on advisory boards for Bayer and Pfizer, and has received research grants from Novartis; PRe has served on advisory boards for Novartis; ESMO Guidelines Comm EURACAN , Rutkowski , P , Safwat , A A , Schöffski , P , Sleijfer , S , Stacchiotti , S , Sundby Hall , K , Unk , M , Van Coevorden , F , Van der Graaf , W T A , Whelan , J , Wardelmann , E , Zaikova , O & Blay , J Y 2018 , ' Soft tissue and visceral sarcomas : ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up ' , Annals of Oncology , vol. 29 , no. Suppl . 4 , pp. 51-67 . https://doi.org/10.1093/annonc/mdy096Test; ORCID: /0000-0003-0281-2507/work/52691550; 85052604766; 59d8cc15-8dd5-4244-8b54-a38ffacec004; http://hdl.handle.net/10138/289727Test; 000448047900005

الإتاحة: http://hdl.handle.net/10138/289727Test

المؤلفون: ESMO Guidelines Comm EURACAN, Casali, P. G., Joensuu, H.

المساهمون: Heikki Joensuu / Principal Investigator, Department of Oncology, Clinicum, HUS Comprehensive Cancer Center

مصطلحات موضوعية: PHASE-II TRIAL, NEOADJUVANT/ADJUVANT IMATINIB MESYLATE, ADJUVANT IMATINIB, RANDOMIZED-TRIAL, CARNEY-STRATAKIS, DOSE IMATINIB, GIST, MUTATIONS, SURGERY, KIT, 3122 Cancers, 3121 General medicine, internal medicine and other clinical medicine

وصف الملف: application/pdf

العلاقة: PGC has reported advisory roles for Deciphera Pharmaceuticals, Eisai, Eli Lilly, Nektar Therapeutics, speaker's honoraria from Eisai, Eli Lilly, Pfizer, PharmaMar, and conducted studies sponsored by Amgen Dompe, AROG Bayer, Blueprint Medicines, Eli Lilly, Daiichi Sankyo Pharma, Epizyme, GlaxoSmithKline, Novartis, Pfizer, PharmaMar; SBa has reported research support from Novartis, Incyte, Blueprint Medicines, has received honoraria or consultation fees from Novartis, Lilly, Pfizer, PharmaMar and Bayer; SBi has reported advisory/consultant roles for Lilly, Bayer, Pfizer, Novartis, Isolfol and Clinigen and conducted studies sponsored by Janssen-Cilag, Eisai and Loxo Oncology; SBo has reported honoraria and travel grants from Nanobiotix and Lilly and received travel grants from PharmaMar; IB has received research funds from Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Roche, Amgen and has reported advisory roles for AstraZeneca, Roche, Merck Sharp & Dohme, LEO Pharma, Amgen, Bristol-Myers Squibb, Pfizer and Novartis; TB has reported honoraria from Roche and PharmaMar and advisory board and honoraria from Amgen, Bayer, Novartis, Eisai and Eli Lilly; JMB has reported consulting advisory role for PharmaMar, Lilly, Bayer, Novartis and being a member of the speaker's bureau for PharmaMar and received travel grants from PharmaMar and Lilly; APDT is a member of the speakers' bureau for Lilly, Pfizer and Merck Sharp & Dohme; XGDM has reported advisory role for Lilly, PharmaMar and Novartis; PD has reported conducted research sponsored by Eli Lilly; ME has participated in advisory boards for Bayer, Sobi, Lilly, Eisai and Novartis; AMF has conducted studies sponsored by Amgen Dompe, AROG Bayer, Blueprint Medicines, Eli Lilly, Daiichi Sankyo Pharma, Epizyme, GlaxoSmithKline, Novartis, Pfizer, PharmaMar; SG has received research grants and honoraria from Novartis, Pfizer and Bayer; HG has received research grants from Novartis, Daiichi Sankyo Pharma and Pfizer; HG has received research grants from Novartis, Daiichi Sankyo Pharma and Pfizer; AG has reported compensation for advisory boards from Novartis, Pfizer, Bayer, Lilly, PharmaMar and Nanobiotix, honoraria from Novartis, Lilly, PharmaMar and Nanobiotix, and research funds from PharmaMar and travel grants from PhramaMar and Nanobiotix; BH has received research grants from EuroSarc and has conducted research with EIT Health in collaboration with GE healthcare and Philips, he has received reagents from Takeda and Astellas to conduct clinical trials without direct funding; PH has reported conducting research sponsored by Novartis, Blueprint Medicines, Nanobiotix and Lilly and has received honoraria and travel grants from PharmaMar, Eisai and Lilly; HJ has reported co-appointment with Orion Pharma and holds stock in Sartar Therapeutics, Faron Pharmaceuticals and Orion Pharma; RLJ is a consultant for Adaptimmune, Blueprint Medicines, Clinigen, Eisai, Epizyme, Daichii, Deciphera, Immunedesign, Lilly, Merck and PharmaMar; IJ has received honoraria from Lilly for lectures; PJ has reported being a consultant for Stryker for the design of a new tumour prosthesis; BK has reported honoraria from Novartis, Pfizer and Bayer and advisory role for Bayer; KK has received travel grants from Novartis and Pfizer; ALC has received honoraria from Pfizer, Novartis, Lilly, Amgen, Bayer and PharmaMar; MAP has served on advisory boards for Bayer and Pfizer, and has received research grants from Novartis; PRe has served on advisory boards for Novartis, Pfizer, PharmaMar, Ariad, Merck, Deciphera, Roche, Clinigen and; ESMO Guidelines Comm EURACAN , Casali , P G & Joensuu , H 2018 , ' Gastrointestinal stromal tumours : ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up ' , Annals of Oncology , vol. 29 , no. Suppl 4 , pp. 68-78 . https://doi.org/10.1093/annonc/mdy095Test; ORCID: /0000-0003-0281-2507/work/50558706; 85054214404; ddbe34a2-336d-4f8b-af16-5bb5005e1ab2; http://hdl.handle.net/10138/306617Test; 000448047900006

الإتاحة: http://hdl.handle.net/10138/306617Test

المؤلفون: Casali, P.G., Blay, J.Y., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Boye, K., Brodowicz, T., Buonadonna, A., Alava, E. de, Tos, A.P. dei, Muro, X.G. del, Dufresne, A., Eriksson, M., Fedenko, A., Ferraresi, V., Ferrari, A., Frezza, A.M., Gasperoni, S., Gelderblom, H., Gouin, F., Grignani, G., Haas, R., Hassan, A.B., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R.L., Jungels, C., Jutte, P., Kasper, B., Kawai, A., Kopeckova, K., Krakorova, D.A., Cesne, A. le, Grange, F. le, Legius, E., Leithner, A., Lopez-Pousa, A., Martin-Broto, J., Merimsky, O., Messiou, C., Miah, A.B., Mir, O., Montemurro, M., Morosi, C., Palmerini, E., Pantaleo, M.A., Piana, R., Piperno-Neumann, S., Reichardt, P., Rutkowski, P., Safwat, A.A., Sangalli, C., Sbaraglia, M., Scheipl, S., Schoffski, P., Sleijfer, S., Strauss, D., Strauss, S.J., Hall, K.S., Trama, A., Unk, M., Sande, M.A.J. van de, Graaf, W.T.A. van der, Houdt, W.J. van, Frebourg, T., Gronchi, A., Stacchiotti, S., ESMO Guidelines Comm, EURACAN, GENTURIS

المساهمون: Casali P.G., Blay J.Y., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Boye K., Brodowicz T., Buonadonna A., De Alava E., Dei Tos A.P., Del Muro X.G., Dufresne A., Eriksson M., Fedenko A., Ferraresi V., Ferrari A., Frezza A.M., Gasperoni S., Gelderblom H., Gouin F., Grignani G., Haas R., Hassan A.B., Hindi N., Hohenberger P., Joensuu H., Jones R.L., Jungels C., Jutte P., Kasper B., Kawai A., Kopeckova K., Krakorova D.A., Le Cesne A., Le Grange F., Legius E., Leithner A., Lopez-Pousa A., Martin-Broto J., Merimsky O., Messiou C., Miah A.B., Mir O., Montemurro M., Morosi C., Palmerini E., Pantaleo M.A., Piana R., Piperno-Neumann S., Reichardt P., Rutkowski P., Safwat A.A., Sangalli C., Sbaraglia M., Scheipl S., Schoffski P., Sleijfer S., Strauss D., Strauss S.J., Hall K.S., Trama A., Unk M., van de Sande M.A.J., van der Graaf W.T.A., van Houdt W.J., Frebourg T., Gronchi A., Stacchiotti S., Medical Oncology, ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Public Health Research (PHR), Man, Biomaterials and Microbes (MBM)

المصدر: Annals of Oncology, 33(1), 20-33. ELSEVIER
ESMO Guidelines Committee, EURACAN and GENTURIS 2022, ' Gastrointestinal stromal tumours : ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up ', Annals of Oncology, vol. 33, no. 1, pp. 20-33 . https://doi.org/10.1016/j.annonc.2021.09.005Test
Annals of Oncology, 33(1), 20-33. Elsevier Ltd.
Annals of Oncology, 33(1), 20-33. Oxford University Press

مصطلحات موضوعية: GIST, clinical practice guidelines, gastrointestinal stromal tumour, surgery, tyrosine kinase inhibitor, Oncology, Medizin, Hematology, clinical practice guideline

وصف الملف: application/pdf; STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db2250913ba4be9bf70a7ea215df219dTest
http://www.scopus.com/inward/record.url?scp=85121969676&partnerID=8YFLogxKTest

المؤلفون: Strauss, S.J., Frezza, A.M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J.Y., Bolle, S., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Boye, K., Brennan, B., Brodowicz, T., Buonadonna, A., Alava, E. de, Tos, A.P. dei, Muro, X.G. del, Dufresne, A., Eriksson, M., Fagioli, F., Fedenko, A., Ferraresi, V., Ferrari, A., Gaspar, N., Gasperoni, S., Gelderblom, H., Gouin, F., Grignani, G., Gronchi, A., Haas, R., Hassan, A.B., Hecker-Nolting, S., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R.L., Jungels, C., Jutte, P., Kager, L., Kasper, B., Kawai, A., Kopeckova, K., Krakorova, D.A., Cesne, A. le, Grange, F. le, Legius, E., Leithner, A., Pousa, A.L., Martin-Broto, J., Merimsky, O., Messiou, C., Miah, A.B., Mir, O., Montemurro, M., Morland, B., Morosi, C., Palmerini, E., Pantaleo, M.A., Piana, R., Piperno-Neumann, S., Reichardt, P., Rutkowski, P., Safwat, A.A., Sangalli, C., Sbaraglia, M., Scheipl, S., Schoffski, P., Sleijfer, S., Strauss, D., Hall, K.S., Trama, A., Unk, M., Sande, M.A.J. van de, Graaf, W.T.A. van der, Houdt, W.J. van, Frebourg, T., Ladenstein, R., Casali, P.G., Stacchiotti, S., ESMO Guidelines Comm, EURACAN, GENTURIS, ERN PaedCan

المساهمون: European Society for Medical Oncology, Strauss S.J., Frezza A.M., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Blay J.Y., Bolle S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Boye K., Brennan B., Brodowicz T., Buonadonna A., de Alava E., Dei Tos A.P., Garcia del Muro X., Dufresne A., Eriksson M., Fagioli F., Fedenko A., Ferraresi V., Ferrari A., Gaspar N., Gasperoni S., Gelderblom H., Gouin F., Grignani G., Gronchi A., Haas R., Hassan A.B., Hecker-Nolting S., Hindi N., Hohenberger P., Joensuu H., Jones R.L., Jungels C., Jutte P., Kager L., Kasper B., Kawai A., Kopeckova K., Krakorova D.A., Le Cesne A., Le Grange F., Legius E., Leithner A., Lopez Pousa A., Martin-Broto J., Merimsky O., Messiou C., Miah A.B., Mir O., Montemurro M., Morland B., Morosi C., Palmerini E., Pantaleo M.A., Piana R., Piperno-Neumann S., Reichardt P., Rutkowski P., Safwat A.A., Sangalli C., Sbaraglia M., Scheipl S., Schoffski P., Sleijfer S., Strauss D., Sundby Hall K., Trama A., Unk M., van de Sande M.A.J., van der Graaf W.T.A., van Houdt W.J., Frebourg T., Ladenstein R., Casali P.G., Stacchiotti S., ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Public Health Research (PHR), Man, Biomaterials and Microbes (MBM)

المصدر: Annals of Oncology, 32(12), 1520-1536. ELSEVIER
Strauss, S J, Frezza, A M, Abecassis, N, Bajpai, J, Bauer, S, Biagini, R, Bielack, S, Blay, J Y, Bolle, S, Bonvalot, S, Boukovinas, I, Bovee, J V M G, Boye, K, Brennan, B, Brodowicz, T, Buonadonna, A, de Álava, E, Dei Tos, A P, Garcia Del Muro, X, Dufresne, A, Eriksson, M, Fagioli, F, Fedenko, A, Ferraresi, V, Ferrari, A, Gaspar, N, Gasperoni, S, Gelderblom, H, Gouin, F, Grignani, G, Gronchi, A, Haas, R, Hassan, A B, Hecker-Nolting, S, Hindi, N, Hohenberger, P, Joensuu, H, Jones, R L, Jungels, C, Jutte, P, Kager, L, Kasper, B, Kawai, A, Kopeckova, K, Krákorová, D A, Le Cesne, A, Le Grange, F, Legius, E, Leithner, A, Safwat, A A, Sangalli, C, Sbaraglia, M, Scheipl, S, Schöffski, P, Sleijfer, S, Strauss, D, Sundby Hall, K, Trama, A, Unk, M, van de Sande, M A J, van der Graaf, W T A, Van Houdt, W, Frebourg, T, Ladenstein, R, Casali, P G, Stacchiotti, S & ESMO Guidelines Committee, EURACAN, GENTURIS and ERN PaedCan. Electronic address: clinicalguidelines@esmo.org 2021, ' Bone sarcomas : ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 32, no. 12, pp. 1520-1536 . https://doi.org/10.1016/j.annonc.2021.08.1995Test
Digital.CSIC. Repositorio Institucional del CSIC
instname
Annals of oncology : official journal of the European Society for Medical Oncology, 32(12), 1520-1536. Oxford University Press

مصطلحات موضوعية: medicine.medical_specialty, diagnosis, Medizin, bone sarcoma, Bone Neoplasm, Bone Sarcoma, Follow-Up Studie, 03 medical and health sciences, 0302 clinical medicine, follow-up, medicine, 030304 developmental biology, Osteosarcoma, 0303 health sciences, treatment, business.industry, Sarcoma, Hematology, Guideline, clinical practice guideline, management, 3. Good health, Clinical Practice, diagnosi, Oncology, Diagnosis treatment, 030220 oncology & carcinogenesis, Radiology, business, Human

وصف الملف: application/pdf; STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bca524e0fe6083fd923a16da0ff377bTest
https://doi.org/10.1016/j.annonc.2021.08.1995Test

المؤلفون: Casali, P, Bielack, S, Abecassis, N, Aro, H, Bauer, S, Biagini, R, Bonvalot, S, Boukovinas, I, Bovee, J, Brennan, B, Brodowicz, T, Broto, J, Brugières, L, Buonadonna, A, De Álava, E, Dei Tos, A, Del Muro, X, Dileo, P, Dhooge, C, Eriksson, M, Fagioli, F, Fedenko, A, Ferraresi, V, Ferrari, A, Ferrari, S, Frezza, A, Gaspar, N, Gasperoni, S, Gelderblom, H, Gil, T, Grignani, G, Gronchi, A, Haas, R, Hassan, B, Hecker-Nolting, S, Hohenberger, P, Issels, R, Joensuu, H, Jones, R, Judson, I, Jutte, P, Kaal, S, Kager, L, Kasper, B, Kopeckova, K, Krákorová, D, Ladenstein, R, Le Cesne, A, Lugowska, I, Merimsky, O, Montemurro, M, Morland, B, Pantaleo, M, Piana, R, Picci, P, Piperno-Neumann, S, Pousa, A, Reichardt, P, Robinson, M, Rutkowski, P, Safwat, A, Schöffski, P, Sleijfer, S, Stacchiotti, S, Strauss, S, Sundby Hall, K, Unk, M, Van Coevorden, F, van der Graaf, W, Whelan, J, Wardelmann, E, Zaikova, O, Blay, J, ESMO Guidelines Committee, PaedCan and ERN EURACAN

العلاقة: https://ora.ox.ac.uk/objects/uuid:3bbe4d67-040f-4edd-9cdf-956a9f405df6Test; https://doi.org/10.1093/annonc/mdy310Test

الإتاحة: https://doi.org/10.1093/annonc/mdy310Test
https://ora.ox.ac.uk/objects/uuid:3bbe4d67-040f-4edd-9cdf-956a9f405df6Test